Carvykti denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for carvykti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Carvykti as Experimental

Aetna may issue an "experimental or investigational" denial for Carvykti (ciltacabtagene autoleucel) when its clinical policy has not been updated to reflect the therapy's FDA approval status, when the requested indication falls outside the specific approved indication as defined in Aetna's policy, or when coverage policy has a lag behind the FDA approval date. Because Carvykti holds FDA approval for its indicated population in relapsed or refractory multiple myeloma, an "experimental" denial for an on-label use is factually incorrect and is one of the most successfully overturned categories of denial for CAR-T therapies.

## Why This Denial Is Appealable

FDA approval is the baseline standard for what constitutes established (non-experimental) therapy under most insurance contracts. If Carvykti is being used within its FDA-approved indication, attaching the FDA approval letter and the current prescribing information directly rebuts the experimental characterization. Your oncologist should also reference the applicable professional society guideline — such as the relevant National Comprehensive Cancer Network (NCCN) guideline category — as evidence that this therapy is consistent with accepted standard of care for your disease stage. Aetna's own clinical policy bulletin should be reviewed for its effective date; if the policy predates FDA approval or has not been updated, note that in your appeal.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 or state insurance law, you are entitled to a full-and-fair internal review. File within the deadline in your denial letter.
• External review: Under ACA §2719, after exhausting internal review you may seek independent external review within approximately four months. External IROs routinely reverse experimental denials when FDA approval documentation is presented.
• Expedited review: Given the urgency of relapsed/refractory multiple myeloma management, request simultaneous expedited external review for a 72-hour decision.

## Documentation to Gather

• FDA approval documentation: Print the Carvykti BLA approval letter and current prescribing information (Drugs@FDA is the authoritative source). Highlight the approved indication and confirm your patient's case falls within it.
• Aetna clinical policy bulletin: Request the current version. Note the effective date and compare it to the FDA approval date.
• NCCN guideline reference: Ask your oncologist to note the applicable NCCN category of evidence and consensus for CAR-T therapy in the relevant multiple myeloma line of therapy (without citing specific page numbers or statistics — direct Aetna to verify in the current NCCN Guidelines).
• Diagnosis and treatment history: Bone marrow biopsy, imaging, response assessments, and a full prior-line-of-therapy summary demonstrating eligibility for the indicated population.
• Oncologist's medical-necessity letter: Should confirm on-label use, address the experimental characterization directly, and cite the FDA approval and guideline support.

## Criteria-Mapping Structure

Build a two-column table: left column lists each requirement in Aetna's experimental/investigational policy and each criterion in the Carvykti clinical policy bulletin; right column cites the specific document satisfying it. Lead with the FDA approval exhibit. This direct evidence-to-criterion mapping eliminates ambiguity and gives the independent reviewer everything needed to render a reversal without requesting additional information.